Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Jan 24



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Jan 24

DOI: 10.23736/S1824-4785.20.03224-0


language: English

Benefit of including CT urography in 68Ga-PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis

Florian ROSAR 1 , Martin J. HÜGLE 1, Martin RIES 1, Mark BARTHOLOMÄ 1, Stephan MAUS 1, Peter FRIES 2, Fadi KHREISH 1, Samer EZZIDDIN 1

1 Department of Nuclear Medicine, Saarland University Medical Center, Homburg, Germany; 2 Clinic of Diagnostic and Interventional Radiology, Saarland University Medical Center, Homburg, Germany


BACKGROUND: Accuracy of 68Ga-PSMA-11 PET/CT may be hampered by ureter accumulation, mimicking lymph node metastases depending on localization and configuration. The benefit of CT urography for differentiation of lymph node metastasis from urinary tract activity was evaluated in a “PET/CT with low-dose CT” setting.
METHODS: Retrospective analysis of PET/CT for primary staging, biochemical recurrence or local treatment planning in patients with prostate cancer. For CT urography (CTU), iodinated contrast agent was administered 10 minutes prior to image acquisition. All potential pathologic (peri)ureteral tracer uptake were assigned to excretory ureteral accumulation or pathological lesion. To assess additional provided benefit of CTU all foci were rated with an introduced scoring system (ranging from 0 pts: CTU not needed, up to 3 pts: no differentiation possible without CTU). Success of ureter contrasting was assessed by measurement of Hounsfield units. Besides benefit for reading urography-enhanced PET/CT, the possible impact on subsequent patient treatment was evaluated.
RESULTS: A number of n=247 patients were included in this study. By CT urography, it was possible to identify each ureter on low-dose CT, with its major part contrasted. In 120/247 (48.6%) patients, urography increased the diagnostic confidence while providing substantial support for interpretation in 60 (24.3%) cases. In 42 (17.0%) patients, urography was clinically relevant (up-/downstaging) with potential impact on subsequent patient care. In 30 of these 42 cases (12.1% of all), discrepant treatment would have resulted from a misdiagnosed tracer accumulation without urography.
CONCLUSIONS: CT urography benefits the interpretation of 68Ga-PSMA-11 PET/CT with low-dose CT and leads to discrepant patient treatment in a small but significant subset of patients (12% in our cohort). The implementation of CT urography into standard protocols of 68Ga-PSMA-11 PET/CT with low-dose CT is recommended.

KEY WORDS: 68Ga-PSMA-11; Contrast media; Prostate cancer; Renal excretion; Lymph node metastasis

top of page